What question did this study set out to answer?

To describe real-world treatment patterns in mantle cell lymphoma and compare healthcare resource utilization and payer costs between ibrutinib-based regimens and chemoimmunotherapy in relapsed or refractory disease.

July 29, 2021Clinical TherapeuticsOpen Access

Treatment Patterns Among Patients With Mantle Cell Lymphoma and Comparison of Healthcare Resource Utilization and Costs Among Relapsed/Refractory Patients Treated With Ibrutinib or Chemoimmunotherapy: A Real-world Retrospective Study

View Full Paper

Ask AI

Bookmark

Authors

NGNilanjan GhoshLevine Cancer Institute BÉBruno ÉmondGroup for Research in Decision Analysis MLMarie‐Hélène LafeuilleGroup for Research in Decision Analysis

Discussion

Member takes

Implication

Retrospective cohort study reveals lower healthcare resource use and total costs with ibrutinib versus chemoimmunotherapy in relapsed mantle cell lymphoma, indicating substantial economic offsets.

Key Points

To describe real-world treatment patterns in mantle cell lymphoma and compare healthcare resource utilization and payer costs between ibrutinib-based regimens and chemoimmunotherapy in relapsed or refractory disease.
Retrospective cohort study using Optum's Clinformatics Data Mart Database (May 2013–June 2019) evaluating 1,346 adults with mantle cell lymphoma who received at least one line of therapy (median follow-up: 15.3 months).
Compared monthly healthcare resource utilization and payer costs in the second or later line between ibrutinib ± rituximab (n=149 weighted) and chemoimmunotherapy (n=151 weighted) using inverse probability of treatment weighting over 6-month episodes and overall regimen duration.
Patients treated with ibrutinib ± rituximab used significantly fewer monthly outpatient service days than those receiving chemoimmunotherapy during the 6-month episode (rate ratio = 0.63, P < 0.001) and throughout the regimen duration (rate ratio = 0.73, P = 0.004).
Higher monthly pharmacy costs for ibrutinib ± rituximab (mean difference: +$9,938 during 6 months, P < 0.001; +$8,920 over full regimen, P < 0.001) were entirely offset by lower medical costs (-$19,373, P < 0.001; -$13,548, P < 0.001).
Total monthly healthcare costs favored ibrutinib ± rituximab, yielding significant net savings during the 6-month episode (mean difference: -$9,435, P < 0.001) and across the total line of therapy (mean difference: -$4,628, P = 0.01).

Cite This Study

Ghosh et al. (2021) studied this question.

synapsesocial.com/papers/6a894f8bb1e5d05ea8ec69b9 https://doi.org/10.1016/j.clinthera.2021.06.012

View Full Paper

Ask AI

Bookmark

Implication

Retrospective cohort study reveals lower healthcare resource use and total costs with ibrutinib versus chemoimmunotherapy in relapsed mantle cell lymphoma, indicating substantial economic offsets.